ClinicalTrials.gov
public full text
Public Domain
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:#811777
- Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration#800768
- Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean#897755
- COMBINATII ( PERINDOPRIL ARGININA + INDAPAMID + AMLODIPINA ) TRIPLIXAM 10MG/ 2.5MG/ 5MG#166404
- COMBINATII ( PERINDOPRIL ARGININA + INDAPAMID + AMLODIPINA ) TRIPLIXAM 5MG/ 1.25MG/ 5MG#166407
Record · ID 807534
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive